Diverse efficacy data for Sinopharm COVID-19 vaccine 'real and valid': Media
02 January, 2021
Diverse efficacy results for a Chinese COVID-19 vaccine released separately in China and on United Arab Emirates are actually both real and valid, an executive at China National Biotec Group (CNBG) told state media.
China approved its first COVID-19 vaccine for public work with on Thursday (Dec 31), a shot produced by an affiliate to state-backed Sinopharm, following the programmer said the vaccine showed 79.34 per cent efficacy based on an interim analysis of late-stage clinical trials.
That rate is lower than the 86 % rate for the same vaccine reported by the United Arab Emirates in Dec 9.
Countries have certain dissimilarities in their standards and procedures found in diagnosing patients, and the ultimate results of COVID-19 case identification were different, Yang Xiaoming, chairman at Sinopharm unit's CNBG, told Global Times, a good tabloid published by the People's Daily, the official newspaper of China's ruling Communist Party.
"Therefore, there were dissimilarities between your comprehensive multi-country data we reviewed and the protection rate data previously evaluated by the UAE and Bahrain," Global Times quoted Yang as saying in a written report published on Thursday.
"But these two results are both real and valid," Yang said, without giving even more details for the info.
CNBG did not take part in the analysis or perhaps overview of clinical trial data released by regulators found in countries where its vaccine was being trialled, Yang said.
The vaccine, developed by CNBG's unit Beijing Biological Products Institute, along with another prospect from a Wuhan-based unit of CNBG, are being tested in Phase III clinical trials outdoor China.
Trials for CNBG's prospects have recruited over 60,000 participants aged between 18 and 60, Yang said.
Useful Links:
Source:
TAG(s):